ADVM
Adverum·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 2
MACD Golden Cross
Significant Revenue Decline
EPS Beats Expectation
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About ADVM
Adverum Biotechnologies, Inc.
A clinical-stage company that develops therapeutics based on novel gene therapies to treat ocular and rare diseases
100 Cardinal Way, Redwood City, California 94063
--
Adverum Biotechnologies, Inc., was founded in Delaware on July 17, 2006. The company is a clinical-stage gene therapy company targeting unmet medical needs for serious rare and eye diseases. Using their next-generation adeno-associated virus (" AAV ") -based directed evolution platform, they generate candidates for gene therapy products designed to provide durable efficacy by inducing sustained expression of therapeutic proteins. Their core competencies include clinical development and in-house manufacturing expertise, particularly in process development, test development and current Good Manufacturing Practices (" cGMP ") quality control.
Company Financials
EPS
ADVM has released its 2025 Q2 earnings. EPS was reported at -2.34, versus the expected -2.28, missing expectations. The chart below visualizes how ADVM has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
